Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Ex-MHLW Official Isobe, Now at Self-Medication Group, Touts OTC Use to Soften Impact of Off-Year Re-Pricing
September 7, 2022
- Chuikyo Payer Rep Eyes 5%-Plus Discrepancy Threshold or Broader Coverage: 2023 Off-Year Re-Pricing
September 5, 2022
- FPMAJ Chief Advocates Drug Price Revision Rule Based on Appropriate Margins for Each Player
September 2, 2022
- JPMA Proposes New Value-Based Pricing System for Innovative Meds, No Price Cut in Patent Period
August 31, 2022
- JPMA Urges Govt to Expand Support to Boost Competitiveness of Japan Pharma Industry
August 31, 2022
- Allocate All Savings from Off-Year Drug Re-Pricing to Medical Fees: Hodanren
August 31, 2022
- JaDHA Hopes to Issue First Policy Proposal to Solve Digital Health Challenges by Year-End: Chairman
August 17, 2022
- Single-Wholesaler Distribution Should Be Redressed from Stable Supply Standpoint: JMA Official
August 4, 2022
- JPWA Chief Questions Patient Benefits of Single-Wholesaler Distribution
August 1, 2022
- Veterans’ Group Proposes Timely Drug Re-Pricing with Online Data, Reimbursement at Actual Purchase Prices
July 27, 2022
- JPMA Delays Announcement of Drug Pricing Proposal
July 27, 2022
- JPMA Hails New Expert Panel, Plans to Raise “Drug Loss” Issue: Director General
July 25, 2022
- Savings from Off-Year Drug Re-Pricing Should Go Towards Medical Fees: JMA Chief
July 15, 2022
- FPMAJ Lauds Ruling Bloc Election Win, Urges Drastic Social Security Debate
July 12, 2022
- FPMAJ Chief Thanks Abe for AMED Launch, Vows to Carry On Innovative Drug Discovery
July 12, 2022
- Regenerative Medicine Makers Have “Good Reasons” to Opt for Single-Wholesaler Route: FIRM Chair
July 12, 2022
- JPMA Think Tank Finds Surge in Japan-Unapproved Drugs in Areas with High Unmet Needs
July 12, 2022
- JPMA Committed to Building Drug Discovery Ecosystem: President
July 5, 2022
- INES Launches Study Group to Propose Stable Healthcare Financing
July 4, 2022
- Generic Use Rate Stands at 79.5% in FY2021: JGA
June 30, 2022
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…